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1. Introduction 
In this review we describe what is recently known about the origin of free nucleic acids in 
human circulation, which processes can cause the elevations of their total concentrations and 
the alterations in the ratios among different types of circulating nucleic acids in human plasma 
and serum. We focus on the inflammatory response and apoptosis with regard to changes in 
the quantity and quality of circulating nucleic acids pool. We discuss the use of cell-free 
nucleic acids as biomarkers in patients with renal failure not only in hemodialysis but also in 
peritoneal dialysis with regard to future perspectives on the field of cell-free nucleic acids. 
2. Origin and clearance of free nucleic acids in human circulation 
The phenomenon of cell-free DNA circulating in human plasma was discovered in 1948 
(Mandel &, Metais, 1948,). The authors detected DNA and RNA in blood plasma of healthy 
control and patients. With regard to the lack of biological understanding of such a finding 
their work remained unnoticed. During next thirty years only two studies focusing on cell-
free DNA appeared. The patients with lupus erythematosus (Tan et al., 1966, in Swarup & 
Rajeswari, 2007) and the patients with rheumatoid arthritis (Ayala et al., 1951) were studied 
and elevated levels DNA in circulation were reported. The medical importance of cell-free 
nucleic acids was recognized when the decreasing levels of these nucleic acids were 
reported in cancer patients after successful chemotherapy (Leon et al., 1977).  
In 1994, mutated oncogene K-ras was discovered in the pool of circulating DNA in pancreatic 
cancer patients (Sorenson at al., 1994). In 1997 the circulating DNA of fetal origin was found in 
plasmas of pregnant women (Lo et al., 1997). Till today numerous studies were performed not 
only to understand the nature and biological meaning of cell-free DNAs and RNAs but mainly 
to establish their diagnostic use under different clinical conditions such as cancer, autoimmune 
disorders, pregnancy related disorders and trauma (for review Tong & Lo, 2006). 
Although recent molecular biology and genetics employ very broad spectrum of 
sophisticated methods, the complete understanding of biology of cell-free nucleic acids was 
so far not achieved. As there are speculations concerning the regulatory function of 
circulating nucleic acids in plasma, the clinical laboratory research and practice stream to 
develop approaches allowing the analytic use of these molecules. The main sources of 
nucleic acids in plasma are necrosis, apoptosis and active release by living, non-apoptotic 
cells. All mentioned processes will be discussed in details in following sections. Cell-free 
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nucleic acids in human plasma present very heterogeneous material with heterogeneous 
function – there are for example fragments of genomic DNA, mitochondrial DNA, but also 
mRNAs and microRNA. The forms in which they circulate are studied also with regard to 
the development of effective extraction methods for clinical laboratories. 
2.1 Necrosis and apoptosis as sources of cell-free DNA 
From the methodological point of view, it is difficult to exactly distinguish between the 
apoptotic derived fraction of cell-free DNA and the necrotic-derived one in plasma. Veiko 
et al. (2008) developed a method for in vivo evaluation of cell death in patients with acute 
and/or chronic heart disease. The main parameters evaluated in the study by Veiko et al. 
were: total concentrations of cell-free DNA (cfDNA) in the blood (or serum), 
concentration of serum ribosomal repeat (rDNA), content of rDNA in total cfDNA, but 
also factors involved in clearance of cfDNA such as nuclease activity and anti-DNA 
antibodies. 
The authors clearly demonstrated significant increase in the concentration of rDNA in the 
cfDNA pool in patients with acute myocardial infarction. Such an accumulation of rDNA 
within cfDNA may be caused by the resistance of rDNA to the fragmentation by serum 
endonucleases, because the nuclease activities in the serum of both acute and chronic 
coronary disease patients were elevated in comparison to healthy individuals. The titers of 
anti-DNA antibodies were also higher in the patients group. The anti-DNA antibodies were 
predominantly bound to cfDNA. It seems that the release of rDNA fragments into the blood 
may reflect cellular death in the body (Veiko et al., 2008). 
Another clinical situation connected with massive cellular death is represented by the 
multiple-organ dysfunction syndrome (MODS). In MODS, the initial insult damages target 
organs and leads to tissue necrosis. The necrosis induces a systemic inflammatory response 
and an alteration of hemodynamics, microcirculation and oxygen metabolism. As a 
consequence, distant organs may be damaged by necrosis or apoptosis. 
The prognostic role of elevated levels of plasma cfDNA in critically ill patients was 
demonstrated by Wijeratne et al. (2004). Pachl et al. (2005) developed an assay allowing to 
distinguish between DNA released from apoptotic and necrotic cells. The assay is based on 
electrophoretic separation of isolated plasma cfDNA fragments on agarose gel. The DNA 
from apoptotic cells (aDNA) is represented by fragments of typical size resembling the 
ladder on an electrophoretic gel, but DNA derived from necrotic cells (genomic - gDNA) 
does not provide this typical pattern when subjected to electrophoretic separation. The 
authors applied their assay on the samples of plasma cfDNA obtained from intensive care 
unit patients. They found that the contribution of aDNA to the amount of total plasma DNA 
in the critically ill patients was 16 fold greater than the contribution of gDNA from necrotic 
cells. The levels of aDNA were highest on the day of admission and declined thereafter, but 
the levels of gDNA altered in the opposite manner. 
The concentration of apoptotic DNA in samples collected from patients on the day of 
admission significantly differentiated survivors and non-survivors (Pachl et al., 2005). The 
study by Pachl confirmed the results of previous research performed on rats (Guan et al., 
2002). The most surprising fact in this context is represented by the finding of the highest 
concentration of  cfDNA of apoptotic origin at the time of patient admission to the intensive 
care unit. The possible explanation for this fact can be found in the induction of apoptosis by 
the activation of the intrinsic pathway caused by the affection of mitochondria as a 
consequence of cellular damage caused by primary insult (Crouser et al., 2002).  
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According to the results obtained in an animal study (Guan et al., 2002) and the first human 
study (Pachl et al., 2005) it seems that primary insult induces apoptosis in the relationship to 
its severity and necrotic DNA originates from secondary organ damage therefore it can be 
detected with later onset during the course of the illness (Pachl et al., 2005). 
Muscle injury caused by athletic overtraining leads also to elevation of plasma cfDNA 
concentrations as reported by Fatouros et al. (2006). The study demonstrated increase of 
cfDNA levels in proportion to training load. Overtraining causes an acute breakdown with 
subsequent repair of skeletal muscle and it is characterized by changes in the functionality of 
immune system resulting in increased susceptibility to infections. The correlation of plasma 
cfDNA with creatinine kinase but not with C-reactive protein was reported in this study. 
The results achieved by Fatouros and coworkers are in good agreement with the results of 
an earlier study (Atamaniuk et al., 2004) in which long-distance runners were examined and 
9- to 17.5 fold increase in concentrations of cfDNA was found immediately after the run. 
With regard to these reports, the extent of physical activities of examined subjects before the 
sampling procedure must be taken in account when evaluating the results of cfDNA based 
studies. The problems concerning the clearance of plasma cfDNA will be discussed in one of 
the following sections. 
2.2 Active release of nucleic acids by cells 
Necrosis and apoptosis were originally sought to be the only sources of cell-free nucleic acids 
in the circulation. The pioneer study by Stroun (2001a) clearly demonstrated the active release 
of fragmented DNA from cells in culture where apoptosis has been inhibited. Anker with 
coworkers (Anker et al., 1976) provided evidence about the release of newly synthesized DNA 
from human leucocytes. They reported that the release process is unrelated to cell death and is 
regulated by a homeostatic mechanism. Precursor incorporation into the DNA was inhibited 
by DNase, RNase, Pronase, and actinomycin D in their experiments. 
The original hypothesis that the tumor specific cfDNA originates from lysis of tumor cells 
on the interface between the tumor and circulation is not more viable with regard to the 
high concentration of cancer specific cfDNA in circulation. Sorenson (1997, in Stroun et al., 
2001a) calculated that 1000 cancer cell per milliliter would be necessary to provide the 
amount of DNA found in the plasma of pancreatic cancer patients. Later, the extraction 
methods for cfDNA were improved, and it has been demonstrated that the concentrations of 
cfDNA in plasma of cancer patients are even ten times higher than originally sought. 
The tumors are not able to supply the circulation with 10 000 cells per each milliliter 
therefore the active release of nucleic acids by tumor cells is recently accepted as the main 
source of cell-free nucleic acids in cancer patients. 
Cell-free DNA can occur in different forms in circulation. It may be transported by vesicle 
based particles, nucleosomes and virtosomes. The extracellular DNA bound in all mentioned 
structures forms the so called nucleome (Peters & Pretorius, 2011). The sequences contained in 
the nucleome were compared with genomic DNA sequences (Stroun et al., 2001; van der Vaart 
& Pretorius, 2008; Beck et al., 2009; Puszyk et al., 2009). Beck et al. studied the nucleome of 50 
healthy individuals and concluded that practically no gene sequence is highly overrepresented 
here in comparison with genomic DNA. 
The overrepresentation of non-coding sequences – Alu repeats – in the nucleome was 
repeatedly reported in studies of this type (Stroun et al., 2001; van der Vaart & Pretorius, 
2008; Beck et al., 2009). Next generation sequencing (high-througput sequencing) has been 
used to analyze and compare the nucleome of healthy controls and patients with breast 
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cancer. The higher representation of certain repetetive elements in the nucleomes of breast 
cancer patients was found and the finding was validated with regard to the diagnostic use 
for staging and outcome prediction (Beck et al., 2010). 
During apoptosis DNA and RNA are packed in separate apoptotic bodies which are rapidly 
ingested by adjacent cells and professional phagocytes. The contribution of apoptotic DNA 
under physiological conditions to the pool of cfDNA is probably insignificant because DNA 
from apoptotic bodies is completely digested by DNAseII in lysosomes of phagocyting cells 
(Peters & Pretorius, 2011). 
Cell-free DNAs are mostly in complex with histones in the form of nucleosomes. The 
association with histones can play the key role in the translocation of cfDNA across cell 
membrane. The binding of cfDNA with histone H3K27me2b was described, this histone 
could be crucial for externalization and stabilization of cfDNA in plasma (Beck et al., 2009). 
It is known for longer time that regulated release of newly synthetized DNA/RNA – 
lipoprotein complexes requires energy. The newly synthetized particles contain DNA, RNA 
DNA-dependent DNA and RNA polymerases, lipoproteins and are referred as  virtosomes. 
Synthesis of DNA for virtosomes probably takes place mainly in the G0 or G1 phase - it 
seems not to be limited to the mitosis (Peters & Pretorius, 2011). 
Not only cell-free DNA can be detected in human plasma, but there is also broad spectrum 
of mRNA and microRNA. Surprisingly, these RNA molecules due their relative stability can 
be also isolated from patient plasma and analyzed in clinical laboratories. Their relative 
stability within the plasma samples is linked to the form in which they are released into 
circulation. These RNA molecules are enclosed in small vesicles referred as exosomes. 
Exosomes are 40 - 100 nm membrane bound vesicles of endocytic origin secreted by most 
cell types in vivo. More than 2,300 proteins and 270 microRNAs have been linked with 
exosomes derived from different biological fluid (Taylor et al., 2011). Exosomes were found 
in vivo in body fluid such as blood, urine, amniotic fluid, malignant ascites, bronchoalveolar 
lavage fluid, synovial fluid and breast milk (Simpson et al., 2008). 
Recently it is not exactly known, if exosomes contains DNA or not. According to the 
research done by García-Olmo et al. (2000) it seems that exosomes can also carry DNA 
containing complexes. 
The advent of genomic and proteomic technologies contributed to the understanding of the 
molecular composition of exosomes, but their biological functions remain still unclear. It is 
becoming apparent that they may be involved in the transfer of both mRNA and microRNA 
to the distant target cells to modulate their expression and behavior. The secretion of 
exosomes by tumor cells and their implication in the transport and propagation of infectious 
cargo such as prions and retroviruses provide the evidence that exosomes are important 
participants of different pathological processes (Simpson at al., 2008). 
The group of García-Olmo demonstrated in an animal study that plasma from tumor-
bearing rats was able to stably transfect cultured cells. The authors proposed a hypothesis 
that the metastasis might occur via transfection of susceptible cells located in distant target 
organ with dominant oncogenes circulating in plasma (García- Olmo et al., 1999) and called 
such a putative phenomenon “genometastasis.” 
One of the most common alterations of tumor related cfDNA is its hypermethylation. The 
methylated DNA fragment have been shown to be taken up by HeLa and human umbilical 
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Recent progress in immunology suggests that nucleic acids are active modulators of the 
immune system. Both RNA and DNA molecules can be detected by specific receptors - the so 
called Toll-like receptors, RIG-I-like receptors and NOD-like receptors (Koyama S. et al., 2010). 
All above mentioned facts contribute to the understanding of cell-free nucleic acids in human 
plasma as important tools in complex regulatory mechanisms involved in homeostasis and 
immune response under frequently changing endo- and exogenous conditions. 
2.3 Clearance of circulating nucleic acids in human plasma 
Cell-free nucleic acids circulate in plasma in different forms as described in previous 
sections. Their clearance and turnover represent very probably complex mechanism which 
is known only superficially. The equilibrium between nucleome and genome forms 
probably the base of genetic homeostasis (Peters & Pretorius, 2011). The individual cells 
from different organs can not only contribute to the pool of nucleic acids in plasma but also 
take part in their turnover using them for regulation of intracellular events in variable extent 
depending on the cell type and physiological state. The live span of the individual molecules 
and complexes determines the area of their effect in which the group of cells can benefit 
from horizontal gene transfer (Peters & Pretorius, 2011). 
Our study (Horinek et al., 2008) brought an indirect evidence for the existence of 
homeostatic mechanisms between nucleic acids released into circulation and taken up by 
cells or digested by nucleases. We measured the concentrations of total cfDNA and fetal 
cfDNA in plasma of healthy pregnant women during pregnancy. Although the 
concentrations of total cfDNA were kept at the same level through the entire pregnancy, the 
fractions of cfDNA of fetal origin in the pool of total maternal cfDNA elevated from the first 
trimestr toward the labor. Lo et al. (1999) reported that fetal DNA is undetectable 2 hours 
postpartum, with a mean half-life of 16.3 min. 
 Under pathological conditions, the clearance of cfDNA can be affected as demonstrated in 
the study by Lau et al. (2002) where higher half-life of fetal DNA in preeclamptic (median 
114 min) women was observed compared to healthy controls (median 28 min). Impaired 
clearance of cfDNA can be expected under other pathological conditions, for example in 
cancer patients. It has been actually documented that the activities of nucleases in cancer 
patient are lowered (Cherepanova et al., 2008). 
It seems that cfDNA in human circulation is present predominantly in the form of 
nucleosomes (Holdenrieder et al., 2001). Liver, macrophages and immune system are mainly 
involved in the clearance of DNA bounded in nucleosomes as has been documented in 
animal model (Burlingame et al., 1996). Kupfer cells are able to degrade the naked DNA on 
their surfaces in a saturable process (Gauthier et al., 1996; Kobayashi et al., 2001). Botezatu et 
al. (2000) demonstrated that kidney is not the main route of elimination of cfDNA from the 
body, only 0,5 % – 2% of the cfDNA passes from bloodstream through kidney into urine. 
This group showed the presence of Y- chromosome sequences in the urine of pregnant 
women carrying male fetuses and detected KRAS mutations in the urine of patients with 
pancreatic and colorectal cancers. 
The study by Chan et al (2010) confirmed that transrenal excretion of cfDNA is very low. 
Sequences of the Epstein- Barr virus they are present in plasma of patients suffering with 
nasopharyngeal carcinoma in high concentrations were used as model system to make the 
detection of cfDNA in urine more robust. Only minor fraction of DNA representing EBV 
sequences was found in the urine of examined patients, this fraction represented 0,0028% - 
0,00018% of the clearance of creatinine. 
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The finding that the cfDNA is stable for at least 4 hours in urine (Su et al., 2005) is important 
for management of clinical samples and translation medicine based on examination of cfDNA 
quantity and quality. From the results of our pilot study (Korabecna et al., 2011) it would 
appear that plasma DNAse II (which is not inhibited in blood samples stabilized by EDTA) 
makes only minor contribution to the degradation of circulating DNA in vitro. If heparin is 
used for sample stabilization nucleases are not inhibited and cfDNA is degraded very quickly. 
3. Concentrations of cell-free nucleic acids in human plasma in health and 
disease 
3.1 Cancer patients 
Numerous studies provided evidence for the value of cfDNA quantification in cancer 
diagnostics and the therapy monitoring. Healthy individuals have in most cases lower 
cfDNA concentrations than cancer patients.  
Today, the study of cell-free DNAs and RNAs in cancer patients is the most fertile area of 
free-nucleic aids research  (8180 articles for key words “cell free nucleic acids and cancer” on 
PubMed till April 2011) 
The qualitative alterations reported in cfDNA in cancer patients include mutations of 
oncogenes and tumor suppressor genes, microsatellite alterations, promoter hypermethylation 
of different cancer related genes and mitochondrial variation. In plasma of cancer patients, the 
existence of tumor specific RNAs detectable with recent methods was reported. 
Detection of circulating RNA in tumor biology has the advantage over DNA-based 
approaches as transcripts can be both tumor and tissue-specific and therefore the origin and 
location of the tumor can be followed. For comprehensive review concerning different 
aspects of the use of circulating nucleic acids as biomarkers in cancer see Vlassov, Laktionov 
& Rykova (2010). 
3.2 Pregnancy related disorders 
Qualitative analysis of fetal cfDNA in maternal circulation has been used for fetal gender 
determination using detection of Y- chromosomal specific sequences, for the detection of 
single gene mutations in fetuses with achondroplasia, myotonic dystrophy, congenital 
adrenal hyperplasia, thalassemia, cystic fibrosis and Huntington disease. Recently, the fetal 
cfDNA is routinely examined to detect the RhD positive fetuses in RhD negative mothers.  
Quantitative aberrations in the concentrations of total levels of cfDNA were found to be 
associated with different pregnancy related disorders such as preeclampsia, various 
placental pathologies, preterm labor, intrauterine growth retardation, polyhydramnion, and 
ectopic pregnancy. Some studies described the elevated values of total cfDNA in maternal 
circulation in pregnancies with aneuploid fetuses, but such results were not satisfactory 
confirmed by others (for review Hořínek et al., 2008). 
3.3 Other diseases 
Elevated plasma levels of cfDNA have been reported to correlate with the severity of injury 
in patients with polytrauma (Lo et al., 2000; Rainer & Lam, 2006) and with the severity of 
stroke (Rainer & Lam, 2006). Another study proposed to use the concentrations of cfDNA in 
plasma for outcome prognosis in acute myocardial infarction (Antonatos et al., 2006). Strong 
correlations were also found between increase of cfDNA in plasma and the outcome of 
intensive care unit patients (Rhodes et al., 2006; Saukkonen et al., 2007). 
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The elevated plasma levels of cfDNA were described to be an excellent marker for graft 
rejection in patients after renal transplantation (García-Moreira et al., 2010). 
3.4 Inflammatory response 
Due to well documented increase in cfDNA levels during inflammatory process (Fatouros et 
al., 2006) it is necessary to take in account the actual health status of control subjects and 
patients with complex clinical diagnosis. The elevated levels of cfDNA interpreted without 
the clinical context can not indicate pathological situations. The actual physical activity of 
examined subjects may also contribute to the elevations of total cfDNA in plasma and serum 
(Atamaniuk et al., 2004; Fatouros et al., 2006). 
The mechanism of immune response to increased amount of nucleosomes in circulation was 
examined in systemic lupus erythematosus (SLE). In this rheumatic autoimmune disease of 
unknown etiology numerous autoantibodies against circulating nucleosomes are produced. 
The production of anti-dsDNA autobodies serves as disease marker for SLE. 
Polymorphonuclear cells, dendritic cells and monocytes strongly bind nucleosomes on their 
surfaces, the binding of nuckeosomes to lymphocytes is weaker. Circulating nucleosomes 
are endocyted in polymorphonuclears, dendritic cells and monocytes. It has been shown in 
polymorphonuclear cells that the nucleosomes are not translocated into nucleus. 
Polymorphonuclear cells represent the link between innate and adaptive immunity 
therefore the perturbations in the regulation of their function could lead to the development 
of autoimmunity (Lindau et al., 2011). 
The role of the receptor TLR9 in the binding of circulating DNA and development of SLE is 
not fully understood. It is known that the TLR9 plays an important role in recognition of 
dsDNA in extracellular space and in its internalization (Lindau et al., 2011) but the 
internalized DNA molecules may stimulate the production of IFN I in dendritic cells also in 
the TLR9–independent pathway (Martin & Elkon,  2006). 
After a hemodialytic procedure, the concentrations of cfDNA in patients are dramatically 
elevated as has been demonstrated in numerous studies (Atamaniuk et al., 2006; Garcia-
Moreira et al., 2006; Korabecna et al., 2008; Horinek et al. 2011). Garcia-Moreira et al. 
reported quite rapid normalization to normal values during 30 min after the end of the 
procedure. The problems associated with the well documented increase of cfDNA during 
the dialytic procedure will be discussed in the following sections. 
The interpretations of each cfDNA based study must be performed carefully with the 
respect to clinical data concerning the presence of autoimmune disease, malignancy, renal 
transplantation or acute infection in examined subjects. All mentioned conditions must be 
used as exclusion criteria. 
For total plasma concentrations of different types of circulating ribonucleic acids, similar 
clinical data are urgently needed. 
4. Cell-free nucleic acids as biomarkers in dialytic process 
During hemodialysis, the interaction of dialyzer membrane with patient´s blood leads to the 
activation of alternate pathway of complement. The biologically active complement 
component C5A is generated and activates the aggregation of neutrophils and their 
adherence to the endothelial surfaces. Neutrophils harvested during hemodialysis exhibit 
altered oxidative response, chemotaxis, aggregation, and adherence (Lewis & Van Epps, 
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1987). Neutrophils have short half-live - under normal conditions they spend approximately 
12h in the circulation and then migrate into normal tissues or are attracted by chemotactic 
stimuli to inflamed tissues. Once in tissues, they do not return back to circulation but 
undergo apoptosis and are cleared by phagocytosis (Savill 1997). 
Direct contact of cell with membranes in dialyzer can also induce apoptosis (Carracedo et al., 
1995). Interaction of cell-surface protein of monocytes with dialysis membrane can stimulate 
mononuclear cells to interact with neutrophils and induce their apoptosis (Nahar et al., 2001). 
Interaction between dialysis membrane and blood leads not only to complement activation but 
also to cytokine synthesis and release. Certain cytokines, such as tumor necrosis factor (TNF) 
and interleukin (IL)-1β 1, component C5a and bacterial lipopolysacchride (LPS) can increase 
neutrophil survival (Colotta et al., 1992; Lee et al., 1993). 
As some interleukins are generated during hemodialysis and activation of monocytes occurs 
it seems that hemodialysis effects are comparable to the pathophysiological mechanisms of 
inflammation and hypersensitivity response (García-Moreira et al., 2006). 
The survival of leucocytes during hemodialysis is influenced by numerous factors  
therefore an analyte which would mirror the complex character of biological events 
during hemodialysis with regard to the impact of the procedure on immune system of 
each individual patient may be very helpful. The study of cell-free nucleic acids seems to 
be a promising approach. In the next sections, the first attempts in this newly arising field 
will be presented. 
4.1 Cell-free nucleic acids in hemodialyzed patients 
The first study focused on the examination of cfDNA was carried out in 1977 by means of 
semiquantitative counter-immunoelectrophoresis (Steinman & Ackad, 1977). It is till today 
the only one study examining the appearance of cfDNA in vitro experiment using 
circulation of fresh blood through dialysis coil. The authors conclude that the passage of 
blood through the coil itself can account, at least in part, for circulating DNA and speculate 
about the leucocytes as the main source of this DNA. 
Fournie et al. (1989) used the detection method based on incorporation of radiolabeled 
nucleotide in nick translation reaction and confirmed the results obtained by Steinman & 
Ackad (1977). In the study by Fournie and coauthors, 45 patients during 99 sessions of 
hemodialysis or hemofiltration were followed. Independently on the method of treatment, 
during the first 3 h of the session the elevations of plasma DNA were observed. The authors 
concluded that the dialytic procedure induces the death of leucocytes on the artificial 
surfaces and the release of their DNA into blood thus is responsible for elevated values of 
extracellular DNA. In this study plasma DNA levels were increased in interdialytic interval 
in 41 out of 99 samples, among samples with elevated cfDNA levels were 18 out of 24 
samples collected from hepatitis B infected person. 
The study performed by Rumore et al. (1992) used the same cfDNA detection method as 
Steinman & Ackad  (1977) and exploited the possibilities of the visualization of radiolabeled 
DNA on electrophoretic gels to demonstrate that in the blood of hemodialyzed patients the 
electrophoretic patterns known from patients with lupus erythematosus (SLE) are clearly 
recognizable. This study documented also by immunoprecipitation that at least the large 
fraction of cfDNA in the blood of hemodialyzed patients circulates in the form of 
nucleosomes like in the patients with lupus erythematosus. The autoradiograms provided 
the picture of DNA samples fragmented in the typical manner with predominance of bands 
corresponding to DNA of 150-200, 400 and in some cases 600 bp.  
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The authors calculated also very carefully the half-live of this fraction of cfDNA and its rate of 
clearance. Their study was limited by selection of patients with postdialytic concentrations of 
cfDNA high inough for performance of experiments. The half-life of cfDNA in blood of 
hemodialyzed patients immediately after hemodialysis was determined as 4 minutes in this 
study. The rate of cfDNA clearance from circulation calculated by authors is equivalent to the 
DNA content of approximately 15 g of a solid tissue such as liver or of the leucocyte content of 
600 ml of whole blood at WBC of 5000/mm3 per day (Rumore et al., 1992). 
Although the nucleosomes were found in the blood of patients after hemodialysis in similar 
amount as in the patients with lupus erythematosus, the hemodialysis itself does not induce 
any autoimmune response. According to their results, Rumore et al. (1992) hypothesized 
that in patients with lupus erythematosus an impairment of mechanism of nucleosome 
clearance contribute to the development of autoimmune disease. 
Atamaniuk et al. (2006) investigated the levels of cfDNA in hemodialyzed patients together 
with markers of early and late apoptosis in leucocytes. For detection of early and late 
apoptosis flow cytometric measurements of annexin V expression in combination with 7-
amino-actinomycin D (7AAD) were used. Annnexin V has high affinity for 
phosphatidylserine which is translocated during early apoptosis from the inner to the outer 
surface of the plasma membrane. The nuclear 7AAD staining is possible only in the late 
apoptosis or in dead cells because the plasma membrane is desintegrated in such stages and 
allows the throughput of the stain into the nucleus. Employing this methodology, the 
leucocyte can be classified as normal (annexin V- and 7AAD-), early apoptotic (annexin V+ 
and 7AAD -), and apoptotic (annexinV + and 7AAD+). Ten patients hemodialyzed on 
synthetic polymer membranes [Fresenius Polysulfone Capillary dialyzers (F6) low-flux] and 
30 healthy subjects were examined in the study. Blood samples from hemodialyzed patients 
were obtained before hemodialysis (HD), after 20 min of HD, at the end of HD. The 
concentrations of cfDNA  in plasma samples were measured using Vistra Green and human 
placental DNA calibrators. The emitted fluorescent signals were measured in the 
LightCycler at 530 nm and reported in picograms per microliters. 
In HD patients the cfDNA levels before hemodialysis were slightly higher than in controls. 
The significant increase was detected after 20 min of HD. The highest values of cfDNA 
concentrations were determined at the end of HD. The cfDNA samples isolated from plasma 
of patients were subjected to agarose gel electrophoresis. In pre-HD samples and in samples 
taken after 20 min of HD the weaker ladders than in samples after HD were observed. 
The fraction of leucocytes in early apoptosis was significantly higher in predialytic interval in 
patients than in controls. The number of apoptotic leucocytes increased during HD. The 
authors conclude that the apoptosis induced by the contact of leucocytes with dialysis 
membrane may be the main source of elevated concentrations of cfDNA during HD sessions. 
Different types of dialysis membrane were examined in the study by García-Moreira et al. 
(2006) performed with regard to their influence on the cfDNA levels in plasma. In this 
study, concentrations of cfDNA were measured first time using real-time quantitative PCR. 
The sequence of β-globin gene was amplified to quantify the total amount of cfDNA in 
plasma samples. To establish the range of normal values, the samples from 100 healthy 
voluntary blood donors were examined. 
Thirty patients on regular HD were studied in 52 sessions. Chronic renal failure in patients 
was caused by diabetic nephropathy (7 patients), glomerulosclerosis (6 patients), 
nephroangioesclerosis (6 patients), chronic pyelonephritis (3 patients), polycystic kidney 
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disease (2 patients), primary amyloidosis (1 patient), renal artery stenosis (1 patient), renal 
transplantation (1patient), and unknown causes (3 patients).The study was designed to 
compare high-flux (n=37) vs. low-flux (n=15) and polysulfone (n=42) vs. modified cellulose 
(n=10) membranes, seven different membranes were used: Arylane H, Tricea 210, HF-80, 
Arylane M6, FX-60, FX-80, and P160. The effect of the dialysis length on cfDNA 
concentration after HD was evaluated. 
Although correct interpretation of the results is difficult with regard to many variable factors, 
cfDNA levels increased more than four-fold in 75% of the patients after HD.  The study by 
García-Moreira et al. (2006) has two priorities: 1/ the real-time PCR method was used for the 
first time to quantify cfDNA; 2/ clear data about the clearance of elevated cfDNA 
concentrations after HD were provided to scientific community. The authors reported a rapid 
decline to normal values within 30 minutes of completing a hemodialysis session. 
In our study (Korabecna et al.,  2008), we  determined not only pre- and post-dialytic cfDNA 
concentrations in patients on hemodialysis (n=17) but we also examined non-dialyzed 
patients with chronic kidney disease (n=20) and patients on peritoneal dialysis (n=18) in 
comparison with healthy volunteers (n=20). We measured the total cfDNA levels using real-
time PCR on GADPH gene. All patients involved in our study were hemodialyzed on high-
flux polysulfone membrane. 
In HD patients, we found elevated postdialytic cfDNA values and reported high 
interindividual variability. We found also patients with lowered cfDNA values after 
hemodialysis. The levels of cfDNA in HD patients in pre-dialytic interval were 
significantly increased when compared with patients with chronic kidney disease and 
patients on peritoneal dialysis but there was no significant difference in comparison with 
healthy persons probably due to the very broad range of cfDNA concentrations obtained 
in our control group. 
It seems that the study of quantitative and qualitative cfDNA parameters with regard to the 
process of hemodialysis can bring very interesting insights into the biological aspect of the 
treatment with important clinical consequences. 
4.2 Cell-free nucleic acids in patients on peritoneal dialysis 
In our study mentioned above (Korabecna et al., 208), we use real-time PCR based on the 
GAPDH gene sequence amplification for quantification of cfDNA in plasma and 
overnight dialysate in patients on peritoneal dialysis. We determined the ratio of dialysate 
cfDNA/plasma cfDNA (P/D ratio) and discovered that this ratio inversely correlates with 
the duration of period for which the person is treated by peritoneal dialysis. The values of 
P/D ratio lower than one were found in patients dialysed for longer time (median 17 
months). 
Ozkaya et al. (2009) studied the plasma cfDNA in children on peritoneal dialysis and 
found significantly elevated values in comparison to healthy children and positive 
correlation with C- reactive protein levels in treated children. 
Samples of peritoneal effluent with regard to their content of cfDNA were examined in the 
study by Pajek et al. (2009) to analyze the impact of PD solution with different biocompatibility 
and cytotoxic properties on the peritoneal membrane cells. Two PD solutions were tested: a 
conventional lactate buffered, acidic solution and a novel, bicarbonate/lactate buffered, 
neutral solution low in glucose degradation products. A significant decrease in appearance of 
cfDNA in effluent was observed with the novel PD solution. 
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5. Future perspectives 
The study of cell-free nucleic acids in connection with hemodialysis promises new clinically 
important findings. Application of new methods – mainly the technology of Next 
Generation Sequencing (NGS) in combination with bionformatics – will bring huge amount 
of qualitative and quantitative data and allow the study of tiny fractions of specific 
sequences on the total circulating nucleic acids background. Recently, no studies focused on 
analysis of microRNA and mRNA in the plasma of hemodialyzed patient are available. 
Probably, such studies will be managed in near future. 
It has been reported that some interleukins are generated during hemodialysis. It is known 
that activated monocytes during HD liberate certain mediators of immune response (Kim et 
al., 2011) therefore the study of individual mechanisms of immune response in patients may 
be very helpful in the process of individualized treatment. Insights into the current character 
of immune response can be achieved through the analysis of the methylation status of 
selected genes using existing arrays technologies. Such high throughput technologies will 
lead to the comparison of hemodialysis effects on the character of immune response in 
different groups of patients with different comorbidities. 
DNA methylation patterns determined at the level of cfDNA in hemodialyzed patiens may 
be predictive of response to specific drugs and drug combinations. 
The clinical studies performed on hemodialyzed patients can also improve the theoretical 
knowledge about the clearance and turnover of circulating nucleic acids in connection to the 
regulatory functions of this extremely interesting class of molecules. 
6. Conclusion 
Today, there are various methodological approaches allowing the quantitative and 
qualitative characterization of cell-free nucleic acids in circulation of hemodialyzed patients. 
The study od cfDNA in plasma during the hemodialysis began 30 years ago and brought 
interesting results concerning the apoptotic origin of at least an important fraction of this 
DNA and increase of its plasma concentration during the hemodialysis session regardless of 
the used membranes and duration of session. In the past decade, the clearance of cfDNA 
from plasma was studied not only in hemodialyzed patients, and it was concluded, that it is 
very rapid (the half-life is given in minutes) and kidney does not play the major role in this 
process. In last years, the attention is paid to the examination of cell-free ribonucleic acids in 
the circulation with regard to their use as biomarkers under different pathological 
conditions. The application of such methodologies in the field of hemodialysis is still 
awaiting for the researchers, as well as the application of high throughput technologies likes 
Next Generation Sequencing and array technologies of different design. The connection of 
new technologies with clinical studies will result not only in clinical benefit but also in 
deeper insight into basic biological mechanisms of intracellular communication, epigenetic 
regulation  and modulation of immune function at the individualized level leading to truly 
personalized medicine.  
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